Dr. Meyer-Franke has extensive industrial experience in drug discovery and assay development and provides support to a number of early stage programs—particularly those with industrial partners—at the Gladstone Center for Translational Research. She is responsible for the assay development for target and drug discovery research for the Gladstone Institutes. Current projects include collaborations with pharmaceutical firms Bristol-Myers Squibb and H. Lundbeck A/S.
Dr Meyer-Franke has over 13 years experience in the pharmaceutical and biotech industry. Prior to joining Gladstone in 2012, she was a scientist at Neurex and most recently was associate director at Elan Pharmaceuticals. She has interests in a number of therapeutic areas in the neurology area including Multiple Sclerosis (MS), Alzheimer’s disease, Parkinson’s disease and stroke. During her association with Neurex and Elan, Dr Meyer-Franke was project leader for a small molecule stroke program, head of MS discovery research and head of a cellular neuroscience group. She has led multidisciplinary project teams in lead discovery and optimization, has a number of key research publications and is an inventor on a number of patents in these therapeutic areas.
Dr. Meyer-Franke earned her master's degree and PhD at the Institute of Neurobiology in Heidelberg, Germany, and did her postdoctoral studies at Stanford University.